A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma

Skin Cancer

Clinical validation of droplet digital PCR assays in detecting BRAF(V600)-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial

Lancet Oncol

Syeda MM, Long GV, Garrett J, Atkinson V, Santinami M, Schadendorf D, Hauschild A, Millward M, Mandala M, Chiarion-Sileni V, Smylie M, Manikhas GM, Dummer R, Wiggins JM, Ali S, Adnaik SB, Tan M, Dajee M, Polsky D

doi: 10.1016/S1470-2045(25)00139-1

Skin Cancer

Long-term follow-up of real-world adjuvant anti-PD1 checkpoint inhibition and targeted therapy in stage III melanoma patients

J Clin Oncol

Lodde GC, Hassel JC, von Wasielewski I, Meier F, Mohr P, Kähler K, Hauschild A, Glutsch V, Stege H, Berking C, Hüning S, Huynh J, Gutzmer R, Reinhardt L, Schilling B, Loquai C, Erdmann M, Stang A, Kowall B, Galetzka W, Roesch A, Tilkorn D, Ugurel S, Zimmer L, Schadendorf D, Forschner A, Livingstone E

doi: 10.1200/JCO-24-02776

Skin Cancer

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study

Eur J Cancer

Luke JJ, Ascierto PA, Khattak MA, Rutkowski P, Del Vecchio M, Spagnolo F, Mackiewicz J, Merino LC, Chiarion-Sileni V, Kirkwood JM, Robert C, Schadendorf D, de Galitiis F, Carlino MS, Dummer R, Mohr P, Odeleye-Ajakaye A, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Long GV

doi: 10.1016/j.ejca.2025.115381

Skin Cancer

Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma

Ann Oncol

Grover P, Lo SN, Li I, Kuijpers AMJ, Kreidieh F, Williamson A, Amaral T, Dimitriou F, Placzke J, Olino K, Vitale MG, Saiag P, Gutzmer R, Allayous C, Bagge RO, Mattsson J, Asher N, Carter TJ, Meniawy TM, Lawless AR, Czapla JA, Warburton L, Gaudy-Marquest C, Grob JJ, Collins RG, Zhang E, Kessels JI, Neyns B, Mehmi I, Hamid O, Julve M, Furness AJS, Margolin KA, Levi-Ari S, Ressler JM, Haque W, Khattak MA, Wicky A, Roberts-Thomson R, Arance A, Warrier G, Schollenberger MD, Parente P, Chatziioannou E, Lipson EJ, Michielin O, Weber JS, Hoeller C, Larkin J, Atkins MB, Essner R, Johnson DB, Sullivan RJ, Nathan P, Schachter J, Lebbe C, Ascierto PA, Kluger H, Rutkowski P, Dummer R, Garbe C, Lorigan PC, Burton E, Tawbi HA, Haanen J, Carlino MS, Menzies AM, Long GV

doi: 10.1016/j.annonc.2025.03.021

Genitourinary Cancer

Predicting the indication for adjuvant radiation therapy according to EAU guidelines among patients with high-risk prostate cancer: a novel multivariable model

Prostate Cancer Prostatic Dis

Siech C, von Kriegstein H, Wenzel M, Cano Garcia C, Le QC, Tennstedt P, Preisser F, Maurer T, Kriegmair M, Chun FKH, Graefen M, Tilki D, Mandel P

doi: 10.1038/s41391-025-01018-y

Skin Cancer

A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research

Eur J Cancer

Amaral T, Nanz L, Higuita LMS, Ascierto P, Berking C, Couselo EM, Donia M, Dummer R, Gutzmer R, Haushild A, Jalving M, Lee R, Lorigan P, Marquez-Rodas I, Michelin O, Nathan P, Robert C, Schadendorf D, Sobczuk P, Flatz L, Leiter U, Garbe C

doi: 10.1016/j.ejca.2024.115160

Skin Cancer

Global Applicability of a Risk Prediction Tool for Sentinel Node Positivity in Patients With Primary Cutaneous Melanoma

JAMA Dermatol

Lo SN, Gjorup C, Chakera AH, Hölmich LR, Moncrieff M, MacKenzie Ross A, Cassell O, Ma J, Weitemeyer MB, Bagge RO, Klausen S, Calsavara VF, Duprat Neto JP, Bertolli E, Ch'ng S, Saw RPM, Shannon KF, Spillane AJ, Nieweg OE, Stretch JR, Mann GJ, Geh JLC, Haydu LE, Martin RCW, Sharon C, Karakousis GC, Kashani-Sabet M, Adigbli G, El Sharouni MA, Gershenwald JE, Scolyer RA, Thompson JF, Varey AHR

doi: 10.1001/jamadermatol.2025.0318

Genitourinary Cancer

Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials

J Clin Oncol

Armstrong AJ, Liu VYT, Selvaraju RR, Chen E, Simko JP, DeVries S, Sartor O, Sandler HM, Mohamad O, Huang HC, Griffin J, Yamashita R, Esteva A, Tran PT, Spratt DE, Carson JH, Peters C, Gore E, Lee SP, Monson JM, Augspurger ME, El-Gayed A, Rodgers JP, McKay R, Morgan T, Feng FY, Nguyen PL

doi: 10.1200/JCO.24.00365

Lung, Respiratory and Thoracic Cancer

Longitudinal recurrence risk of adjuvant cytotoxic chemotherapy and gefitnib in resected lung cancer: A combined analysis of phase III studies

Lung Cancer

Akamatsu H, Nishikawa T, Takeda Y, Misumi T, Aoki T, Shoda H, Yamashita M, Sakakura N, Daga H, Sugawara S, Okishio K, Kenmotsu H, Yamamoto N, Tada H, Tsuboi M, Mitsudomi T

doi: 10.1016/j.lungcan.2025.108437

Related content

Clinical validation of droplet digital PCR assays in detecting BRAF(V600)-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial

Long-term follow-up of real-world adjuvant anti-PD1 checkpoint inhibition and targeted therapy in stage III melanoma patients

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study

Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma

Predicting the indication for adjuvant radiation therapy according to EAU guidelines among patients with high-risk prostate cancer: a novel multivariable model

A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research

Global Applicability of a Risk Prediction Tool for Sentinel Node Positivity in Patients With Primary Cutaneous Melanoma

Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials

Longitudinal recurrence risk of adjuvant cytotoxic chemotherapy and gefitnib in resected lung cancer: A combined analysis of phase III studies